stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Return on assets
Maravai LifeSciences Holdings, Inc.'s return on assets over the twelve months to 30 September 2026 was −9.06%, up 5.6 percentage points from fiscal 2025 (−14.7%). Over the past ten years it has ranged from −14.7% (fiscal 2025) to 11.4% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −14.7% | (3.09) |
| FY2024 | −11.6% | (5.30) |
| FY2023 | −6.31% | (16.79) |
| FY2022 | 10.5% | (0.94) |
| FY2021 | 11.4% | 3.10 |
| FY2020 | 8.32% | 9.12 |
| FY2019 | −0.80% | 0.86 |
| FY2018 | −1.66% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 13.3% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −3.44% |
| MRVI Maravai LifeSciences Holdings, Inc. | −9.06% |
| VIR Vir Biotechnology, Inc. compare | −17.3% |
| TRVI Trevi Therapeutics, Inc. compare | −19.0% |
| MAZE Maze Therapeutics, Inc. compare | −32.0% |
| REPL Replimune Group, Inc. compare | −71.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)